Search Results
Your search for ,ARE matches 21416 pages
Showing 5151 - 5200
Kieron M. Dunleavy, MD: Update on Primary Mediastinal B-Cell Lymphoma
Kieron M. Dunleavy, MD, of Georgetown University, offers insights into the latest data on treating patients with primary mediastinal B-cell lymphoma: the optimal regimen; whether radiotherapy or stem cell transplants are needed; new information on the biology of the disease; novel agents such as...
Biomarker May Help to Predict Response to Gemcitabine for Patients With High-Grade Serous Ovarian Cancer
For more than 2 decades, the chemotherapy agent gemcitabine has been a mainstay treatment for several types of cancer. Now, scientists have uncovered genetic evidence of which patients with high-grade serous ovarian cancer are likely to benefit from the drug. In a study published by Panagiotis...
Study Finds Genetic Predisposition to Higher Lymphocyte Production May Lead to Higher ALL Risk
Research published by Kachuri et al in the American Journal of Human Genetics reveals that children born with a genetic predisposition to produce more lymphocytes—particularly in relation to other types of white blood cells—may be at a higher risk of developing acute lymphoblastic leukemia (ALL)....
Effectiveness of mRNA COVID-19 Vaccination in Preventing Symptomatic Infection in Health-Care Personnel
As reported in The New England Journal of Medicine by Pilishvili et al for the Vaccine Effectiveness among Healthcare Personnel Study Team, a case-control study has shown that full vaccination with the COVID-19 mRNA vaccines was highly effective in preventing symptomatic COVID-19 infection in U.S....
Triplet Therapy and Lenalidomide Maintenance to Prevent Disease Progression in High-Risk Smoldering Myeloma
In a single-center phase II trial reported in JAMA Oncology, Kazandjian et al found that triplet therapy with carfilzomib, lenalidomide, and dexamethasone (KRd), followed by lenalidomide maintenance, produced high rates of measurable residual disease (MRD)-negative complete response and freedom...
International Survey on Access to Cancer Medicines Considered Essential by Oncologists
An international cross-sectional survey reported in The Lancet Oncology by Fundytus et al found that access to cancer medicines considered essential by oncologists is lacking across the spectrum of low- and lower middle–income to high-income countries. As stated by the investigators, “The World...
Is MRI Cost-Effective for Detecting Cancer in Women With Very Dense Breasts?
A new paper published by Geuzinge et al in the Journal of the National Cancer Institute indicates that adding magnetic resonance imaging (MRI) scans to mammography is cost-effective for detecting breast cancer in women with very dense breasts. About 10% of women have extremely dense breasts, and...
Efficacy of Risk Calculator in Treating Elderly Patients With Cancer
Researchers have shown that using a validated risk calculator helped to drive informed treatment decisions in older patients with cancer. Mbewe et al identified the Cancer and Aging Research Group (CARG) calculator as a quick and helpful tool in assessing chemotherapy toxicity probability in...
Study Shows Benefits of a Next-Day Access Program for Patients With Cancer
A pilot program developed by researchers at Yale Cancer Center that offers patients next-day access for oncologic consultation showed reduced wait times for initial access to cancer care and increased patient satisfaction, according to a new report presented by Mougalian et al at the 2021 ASCO...
Classifying EGFR Mutations by Structure and Function May Help to Match Patients With NSCLC to More Effective Treatments
Researchers have discovered that grouping EGFR mutations by structure and function provides an accurate framework to match patients with non–small cell lung cancer (NSCLC) to the right drugs. The findings, published by Robichaux et al in Nature, identify four subgroups of mutations and introduce a...
Overall Survival With the Bispecific Fusion Protein Tebentafusp for Metastatic Uveal Melanoma
In an interim analysis of the phase III IMCgp100-202 trial reported in The New England Journal of Medicine, Nathan et al found that tebentafusp, a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector, significantly improved overall survival vs...
Are Rates of Hepatocellular Carcinoma Rising in Rural Areas of the United States?
Historically, rates of hepatocellular carcinoma (HCC) have been lower in rural areas than urban regions. However, a recent study published by Zhou et al in Clinical Gastroenterology and Hepatology shows that while cases of HCC have begun slowing in urban communities in the United States, the...
Active Living After Cancer Program May Improve Physical Functioning for Breast Cancer Survivors
Breast cancer survivors who participated in Active Living After Cancer, an evidence-based 12-week group program, markedly increased their physical activity and ability to accomplish the basic pursuits of daily life, reported Tami-Maury et al in the journal Cancer. The results show the program could ...
New Study Aims to Measure Success of Phase III Oncology Trials
New research published by Shen et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that more than 80% of therapies tested in phase III oncology trials did not achieve meaningful clinical benefit in prolonging survival. The researchers analyzed 362 industry-sponsored phase...
Capecitabine Maintenance After First-Line Therapy for Metastatic Colorectal Cancer
In the FOCUS4-N trial reported in the Journal of Clinical Oncology, Adams et al found that capecitabine maintenance improved progression-free—but not overall—survival vs active monitoring in patients with stable disease or objective response after first-line therapy for metastatic colorectal...
The Wistar Institute Recruits Vaccine Researcher Amelia Escolano, PhD, and Immunologist Nan Zhang, PhD, as Assistant Professors
The Wistar Institute, an international biomedical research leader in cancer, immunology, and infectious diseases, has appointed Amelia Escolano, PhD, and Nan Zhang, PhD, as Assistant Professors. Dr. Escolano’s research focuses on the development of novel vaccine approaches against highly mutating ...
Breathing Properly May Help You Live Longer
Every system in the body relies on oxygen. From cognition to digestion, effective breathing not only provides us with a greater sense of mental clarity, but it can also help us sleep better, digest food more efficiently, improve our body’s immune response, and reduce stress levels. According to...
New Chief of Thoracic and Head and Neck Medical Oncology Named to New Jersey Cancer Center
Expanding its multidisciplinary teams of experts focused on the management of head and neck cancers as well as cancers of the lungs, pleura, and mediastinum, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have welcomed Missak Haigentz, Jr, MD, as Chief of Thoracic and Head and Neck...
A Deadly Superbug Launches a Medical Life-and-Death Drama
According to the World Health Organization (WHO), antibiotic resistance is one of the biggest threats to global health, food security, and development today. These highly resistant bacteria cause more than 750,000 deaths worldwide every year, a number that is predicted to rise dramatically....
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Brunei Darussalam
With a population under half a million people, Brunei Darussalam is a small equatorial nation in Southeast Asia. Bordered by the South China Sea on the north, Brunei Darussalam is surrounded on all other sides by Malaysia, which separates the nation into two noncontiguous parts. Nearly two-thirds...
Older Adults With Primary CNS Lymphoma: Treatment Opportunities and Challenges
The ASCO Post is pleased to present the Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib, Desai, and DeAngelis explore the treatment of older patients with primary central nervous system lymphoma (PCNSL), which pose...
Pembrolizumab and Lenvatinib in Advanced Endometrial Carcinoma
On July 21, 2021, pembrolizumab in combination with lenvatinib was granted regular approval for treatment of patients with advanced endometrial carcinoma that is not microsatellite instability–high or mismatch repair–deficient who have disease progression following prior systemic therapy in any...
Kombucha
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien Hou, PharmD, DipIOM, LAc, and Jyothirmai Gubili, MS, focus on...
Paradox Between Cost and Hematopoietic Cell Transplant Rate in Latin America
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Gregorio Jaimovich, MD, Director of the Bone Marrow Transplant Program at Favaloro University Hospital in Buenos Aires. Distinguished expert on radiation therapy and bone...
Gastrointestinal Oncologist Katherine Van Loon, MD, MPH: A Pioneer in Global Oncology
Katherine Van Loon, MD, MPH, was raised in Miami, until the age of 12, and then her family relocated to Atlanta, where she spent her junior and high school years. “If you ask my parents about my decision to become a doctor, they will say I first declared it at age 5. Nobody knew how that idea came...
Nivolumab for Adjuvant Treatment of Urothelial Carcinoma
On August 19, 2021, the PD-1 inhibitor nivolumab was approved for adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection.1 This is the first approval by the U.S. Food and Drug Administration for adjuvant treatment of patients...
Lenvatinib Plus Pembrolizumab for First-Line Treatment of Advanced Renal Cell Carcinoma
On August 10, 2021, the combination of lenvatinib plus pembrolizumab was approved for first-line treatment of adults with advanced renal cell carcinoma.1,2 Supporting Efficacy Data Approval was based on findings from the three-arm, open-label, phase III CLEAR trial (Study 307/KEYNOTE-581;...
IASLC Announces Lifetime Achievement Awards
In conjunction with the 2021 World Conference on Lung Cancer, the International Association for the Study of Lung Cancer (IASLC) presented the following lifetime achievement awards. Paul A. Bunn, Jr, Scientific Award David Carbone, MD, PhD, received the Paul A. Bunn, Jr, Scientific Award. This...
Guideline Rapid Update Provides New Direction on the Care of Patients With Residual Disease in Locally Advanced Esophageal Cancer
An ASCO guideline rapid update is revising recommendations for the management of locally advanced esophageal carcinoma to include provision of nivolumab following adjuvant chemoradiotherapy and surgery. The new guidance addresses treatment of patients with residual disease following resection and...
Conquer Cancer Updates Mission, Vision; Adopts Values Inspired by Its Donors
To underscore its commitment to scale and grow cancer research funding and to align more closely with ASCO, Conquer Cancer®, the ASCO Foundation, has updated its mission and vision. Mission: Accelerate breakthroughs in lifesaving research and empower people everywhere to conquer cancer. Vision: A...
New Evidence Drives Need for Revised Guideline on Hormone-Sensitive Advanced Breast Cancer
A recently updated ASCO guideline offers both new and revised guidance on the treatment of hormone receptor–positive, HER2-negative metastatic breast cancer.1 “ASCO regularly updates its guidelines to make sure everything is current and valuable for oncologists and patients. About a year ago,...
Minnesota Senator Amy Klobuchar Announces Breast Cancer Diagnosis
On September 10, 2021, Senator Amy Klobuchar (D-MN) released the following statement: “I wanted to share an update about my health. In February of this year, doctors at Mayo Clinic found small white spots called calcifications during a routine mammogram. After this was discovered, I had a biopsy...
Building a ‘Better Normal’ of Oncology Care to Strengthen Global Health Security After the COVID-19 Pandemic
During the opening session of the 2021 ASCO Annual Meeting, Julio Frenk, MD, PhD, MPH, President of the University of Miami, gave a riveting presentation in which he described the devastating effects of the global COVID-19 pandemic on patients with cancer as well as on fragile and fragmented...
Myeloma Trial Updates: Focus on High-Risk Patients and Measurable Residual Disease Negativity
Newly diagnosed patients with multiple myeloma deemed at high risk for disease progression may achieve sustained measurable residual disease (MRD) negativity with newer regimens and transplantation, and this may translate into longer progression-free survival. That’s the key take-away message from...
PEACE-1 and STAMPEDE Trials: Abiraterone Acetate Plus Prednisolone in Prostate Cancer
A novel combination of well-known drugs may prolong survival in patients with prostate cancer, according to late-breaking research presented at the European Society for Medical Oncology (ESMO) Congress 2021. The PEACE-1 and STAMPEDE studies found that the addition of abiraterone acetate plus...
Adoptive Cell Therapy May Soon Be Available for Patients With Melanoma
Oncologists who treat patients with melanoma will need to become familiar with another immunotherapy approach. For refractory metastatic disease, adoptive cell therapy is on the horizon. “Adoptive cell therapy will offer additional hope for our patients with melanoma. We’ll likely be seeing this...
Belzutifan for Cancers Associated With von Hippel-Lindau Disease
On August 13, 2021, belzutifan, a hypoxia-inducible factor inhibitor, was approved for treatment of adults with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors but do not...
Dostarlimab-gxly for Mismatch Repair–Deficient Recurrent or Advanced Solid Tumors
On August 17, 2021, dostarlimab-gxly, aPD-1 blocking monoclonal antibody, was granted accelerated approval for adults with mismatch repair–deficient (dMMR) recurrent or advanced solid tumors, as determined by a U.S. Food and Drug Administration (FDA)-approved test, who have had disease progression...
Nivolumab Plus Chemotherapy Improves Survival in Advanced Gastric and Esophageal Adenocarcinomas: Now to Figure Out the Details in These Heterogeneous Diseases
There is no doubt that subsets of patients with esophageal and gastric cancers benefit from immune checkpoint inhibitor therapy. The complexity lies in identifying the appropriate histology, tumor location, expression of programmed cell death receptors and ligands, mechanism of checkpoint...
ASCO 2021: Roundup of Studies You May Have Missed
As ASCO Annual Meeting attendees know by now, clinicians don’t have to be at McCormick Place to hear practice-changing findings and forward-looking advances in the field of oncology. Interesting content was no exception at the 2021 conference, so in addition to covering the biggest news from the...
Study Examines Efficacy of Sunitinib in Malignant Pheochromocytoma and Paraganglioma
The first randomized study in patients with malignant pheochromocytoma and paraganglioma has found that sunitinib prolongs progression-free survival by more than 5 months. The late-breaking results of the FIRSTMAPPP trial were presented by Eric Baudin, MD, PhD, and colleagues at the European...
Lymphoid Malignancies: What’s Next for Antibody-Drug Conjugates?
Antibody-drug conjugates are improving outcomes of patients with lymphoma, often those who have exhausted treatment options after chimeric antigen receptor (CAR) T-cell therapy. Four available antibody-drug conjugates are in the clinic, with brentuximab vedotin moving into the front-line...
Putting Radiotherapy to Best Use With CAR T-Cell Therapy in Lymphoma
The integration of radiation therapy into chimeric antigen receptor (CAR) T-cell therapy may improve outcomes for patients with relapsed or refractory lymphoma, according to Charles A. Enke, MD, Professor and the Bill Bures and Jerry Pabst Chair in Radiation Oncology at the Fred and Pamela Buffett...
Bispecific Antibodies Find a Place in B-Cell Lymphoma Treatment
In relapsed or refractory B-cell lymphomas, bispecific T-cell engager antibodies are finding a place in the treatment algorithm, said Christopher Flowers, MD, MS, FASCO, Professor and Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, Houston. At the...
Patients First
By the time my non–small cell lung cancer was diagnosed in 2004, it had already reached stage IIIB, and I was told there was little that could be done for me. I was 56, a wife, the mother of 3 children, and at the peak of my career as president of Olympian Oil. Although my aunt, brother, and...
Overcoming the Disparities in Cancer Survival Among AYA Minority Patients
Although the National Cancer Institute (NCI) has identified adolescents and young adults (AYAs) with cancer as a distinct patient population from children and older adults with the disease, research into the diagnosis, treatment, and survivorship specific to this patient population has not kept...
BRAF-Mutant Colorectal Cancer: Latest Findings for Targeted Treatment
The phase II ANCHOR CRC study, the largest prospective study of BRAF inhibitor–based therapy as first-line treatment of metastatic colorectal cancer, has met its primary endpoint, with 47.8% of patients with metastatic colorectal cancer responding to first-line treatment with encorafenib,...
First-Line Acalabrutinib, Venetoclax, and Obinutuzumab for Chronic Lymphocytic Leukemia
In a phase II study reported in The Lancet Oncology, Matthew S. Davids, MD, and colleagues found that first-line triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab produced measurable residual disease (MRD)-negative complete remission in a substantial proportion of patients ...
Ruxolitinib Granted FDA Approval for Chronic Graft-vs-Host Disease
On September 22, the U.S. Food and Drug Administration approved ruxolitinib (Jakafi), a JAK inhibitor, for the treatment of chronic graft-vs-host disease (GVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older. REACH3 Efficacy was...
Benjamin Besse, MD, PhD, on NSCLC: A Vaccine Under Study to Treat Advanced Disease
Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, discusses final phase III findings from the Atalante-1 trial, which explored the question of whether the OSE2101 vaccine is more beneficial than standard treatment for patients with HLA-A2–positive non–small cell lung cancer after immune...
